Beijing Beilu Pharmaceutical (300016.SZ): Hydrochloride Dextromethorphan Chemical Raw Material Approved for Market Launch

Beijing Beilu Pharmaceutical (300016.SZ) announced that the company has recently received a notification of approval for the market application of chemical raw material drug hydrochloride lidocaine issued by the National Medical Products Administration. It is reported that hydrochloride lidocaine has local anesthesia, analgesic, anti-itch, and antibacterial effects. Its mechanism of action is to block nerve impulse conduction, inhibit nerve endings, reduce local nerve sensitivity, and thus provide surface anesthesia and pain relief effects. Clinical applications include local anesthesia for endoscopic examinations, pain and itch relief for skin and mucous membranes, and reduction of skin sensitivity.